SCHEMBL6093038

SCHEMBL6093038

CC(C)c1ccc(C(=O)C=CC23CC4CC(CC(C4)C2)C3)cc1

nearest known ligand 0.41

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HDAC1 Q13547 2/20 0.41
HDAC4 P56524 1/20 0.41
HDAC6 Q9UBN7 1/20 0.41
KDM4E B2RXH2 3/20 0.40
LMNA P02545 2/20 0.40
MAPT P10636 2/20 0.40
RAB9A P51151 2/20 0.40
GABBR2 O75899 1/20 0.40
GABBR1 Q9UBS5 1/20 0.40
P2RX7 Q99572 2/20 0.40
CXCL12 P48061 1/20 0.40
MEN1 O00255 3/20 0.38
KMT2A Q03164 3/20 0.38
ALDH1A1 P00352 3/20 0.37
SMN1; SMN2 Q16637 2/20 0.37
MAPK1 P28482 1/20 0.36
CYP2C9 P11712 1/20 0.36
POLB P06746 2/20 0.36
HPGD P15428 2/20 0.36
P2RX4 Q99571 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6090897 0.84 P2RX7 (0.46) KDM4ELMNAMAPTRAB9AP2RX7
SCHEMBL18317449 0.81 RAB9A (0.45) LMNAMAPTRAB9AP2RX7MEN1
SCHEMBL6092092 0.81 TNFRSF1A (0.47) MAPTRAB9AP2RX7ALDH1A1SMN1; SMN2
SCHEMBL6091141 0.80 FAAH (0.49) KDM4ELMNAMAPTRAB9AP2RX7
SCHEMBL6093069 0.80 ALDH1A1 (0.43) HDAC6LMNAMAPTRAB9AMEN1
SCHEMBL6090662 0.80 MAPT (0.48) KDM4ELMNAMAPTRAB9AMEN1
SCHEMBL6093635 0.80 CNR2 (0.55) LMNAMAPTRAB9AP2RX7MEN1
SCHEMBL6092329 0.78 KMT2A (0.48) KDM4ELMNAP2RX7MEN1KMT2A
SCHEMBL3431570 0.72 GPR52 (0.42) HDAC1KDM4EMAPTMEN1KMT2A
SCHEMBL4729401 0.72 MAOA (0.47) KDM4ELMNAMAPTMEN1KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20060074083-A1 Cyclic and acyclic propenones for treating CNS disorders MERZ PHARMA GMBH & CO. KGAA (DE) 2006-04-06 US claimed
US-20060074083-A1 Cyclic and acyclic propenones for treating CNS disorders MERZ PHARMA GMBH & CO. KGAA (DE) 2006-04-06 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060074083-A1 Cyclic and acyclic propenones for treating CNS disorders PMP22, ADCYAP1R1, CYP11B2 HDAC1 1878/4885HDAC4 1113/4885HDAC6 394/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.